Log in to save to my catalogue

An integrin [β.sub.3]-KRAS-RalB complex drives tumour stemness and resistance to EGFR inhibition

An integrin [β.sub.3]-KRAS-RalB complex drives tumour stemness and resistance to EGFR inhibition

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_gale_infotracmisc_A369064229

An integrin [β.sub.3]-KRAS-RalB complex drives tumour stemness and resistance to EGFR inhibition

About this item

Full title

An integrin [β.sub.3]-KRAS-RalB complex drives tumour stemness and resistance to EGFR inhibition

Publisher

Nature Publishing Group

Journal title

Nature cell biology, 2014-05, Vol.16 (5), p.457

Language

English

Formats

Publication information

Publisher

Nature Publishing Group

More information

Scope and Contents

Contents

Tumour cells, with stem-like properties, are highly aggressive and often show drug resistance. Here, we reveal that integrin [α.sub.v][β.sub.3] serves as a marker of breast, lung and pancreatic carcinomas with stem-like properties that are highly resistant to receptor tyrosine kinase inhibitors such as erlotinib. This was observed in vitro and in m...

Alternative Titles

Full title

An integrin [β.sub.3]-KRAS-RalB complex drives tumour stemness and resistance to EGFR inhibition

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_gale_infotracmisc_A369064229

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_gale_infotracmisc_A369064229

Other Identifiers

ISSN

1465-7392

DOI

10.1038/ncb2953

How to access this item